Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XTR020
- Development stage
- Unknown
- Lead developer
- Sinotau Pharmaceutical Group
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
XTR020 is an innovative radiopharmaceutical developed by Sinotau Pharmaceutical Group for the diagnostic imaging of prostate cancer. It is a positron emission tomography (PET) tracer labeled with Fluorine-18 (18F) that specifically targets prostate-specific membrane antigen (PSMA), a cell-surface protein that is significantly overexpressed in prostate cancer cells compared to normal tissues. By binding to PSMA, XTR020 allows for the high-resolution detection and staging of primary and metastatic prostate cancer lesions. As of early 2024, the drug has completed the enrollment and dosing of subjects in a Phase III clinical study in China, making it a late-stage candidate in Sinotau's oncology imaging pipeline.
- Other names
- 18F-labeled PSMA-targeted PET tracer18F-PSMA PET tracer
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on XTR020.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XTR020.